Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 343 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07348055RecruitingPhase 1/Phase 2
A study of GR1803 for lupus
This trial tests a new drug called GR1803 for people with systemic lupus erythematosus (SLE), an autoimmune disease that causes inflammation. It may help reduce disease activity when standard treatments haven't worked well enough.
Wuhan, HubeiAges 18–60 - NCT07397728Recruiting
TREX1 gene changes in lupus with skin rashes
This trial tests for a specific gene change (in the TREX1 gene) in people with lupus, especially those who have lupus-related skin rashes. It aims to understand how this gene may affect the disease.
Qina, South ValleyAges 18–60 - NCT00001372Recruiting
Understanding Lupus: Research Study at NIH
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
Bethesda, MarylandAges 3–120 - NCT01510067Recruiting
Study of skin lupus types and how severe they are
This study looks at adults with cutaneous lupus (skin lupus) and/or systemic lupus (a whole-body autoimmune condition) to understand how common it is and how severe the skin symptoms become. It may help researchers better describe different skin lupus forms and their impact.
Philadelphia, PennsylvaniaAges 18 years+ - NCT00756769Recruiting
Gullah community study for lupus symptoms and risk factors
This study looks at lupus in people from the Gullah community in South Carolina, including people with lupus and healthy comparison participants. It may help researchers better understand who is at risk and how lupus shows up in this community.
Charleston, South CarolinaAges 2 years+ - NCT02954939Recruiting
Test medicines to change immune cells in lupus kidney flare
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
Hong KongAges 18–80 - NCT07405970RecruitingPhase 3
Testing MIL62 for active lupus
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
BeijingAges 18–80 - NCT07440537RecruitingPhase 2
Testing ICP-488 for active cutaneous lupus (skin lupus)
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
Hefei, AnhuiAges 18–75 - NCT06535412RecruitingPhase 1/Phase 2
Study of IMC-002 for active lupus
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
BeijingAges 18–65 - NCT07666711Recruiting
Kidney biomarker study for lupus patients
This study aims to find better ways to detect kidney problems in people with lupus by testing blood and urine samples. If you have lupus, you may help researchers improve how kidney disease is diagnosed and monitored.
Oslo, OsloAges 18 years+ - NCT07394361Enrolling by invitation
Clinical Pilates for women with lupus: fatigue and quality of life
This study tests whether clinical Pilates training can help reduce fatigue, improve mood, sleep, and overall quality of life in women with systemic lupus erythematosus. If you have low disease activity and are not already exercising regularly, you may be able to participate.
Adana, SaricamAges 18–55 - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06661213Enrolling by invitationEarly Phase 1
Tapinarof cream for lupus skin lesions
This study tests if a cream called tapinarof can improve skin symptoms in people with chronic or subacute cutaneous lupus erythematosus (CLE). The goal is to see if it reduces redness, scaling, and thickness of active lesions.
Chicago, IllinoisAges 18 years+ - NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT05097365Enrolling by invitation
Testing a methyl-donor supplement to study lupus metabolism
This study looks at whether a “methyl-donor” nutrient supplement changes metabolism (methylation) in people with lupus who are also in the childbearing age range and have low-to-moderate disease activity. It may help researchers understand why lupus acts differently in some people and how diet-related pathways could affect symptoms.
São PauloAges 18–45 - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Lawrenceville, GeorgiaAges 16 years+ - NCT07203404RecruitingEarly Phase 1
A study of a universal CAR-T cell therapy for autoimmune diseases
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07089121RecruitingPhase 1/Phase 2
Descartes-08 for young people with autoimmune diseases
This trial tests a new therapy called Descartes-08 for children, teens, and young adults with autoimmune conditions like lupus, myasthenia gravis, or dermatomyositis. It aims to see if it can help control moderate disease that hasn't responded well enough to other treatments.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06217107Recruiting
Wellness and work support for lupus and lupus nephritis
This study tests a wellness and work support program for women with lupus or lupus nephritis. The goal is to help you manage your health and connect with others through an online program.
Atlanta, GeorgiaAges 18 years+ - NCT04833465Recruiting
Testing a new outcome measure in kids with rheumatology diseases
This study looks at how to measure treatment success in children with juvenile idiopathic arthritis (JIA), lupus (SLE), or fibromyalgia (FM). It may help doctors track symptoms more reliably over time.
Washington D.C., District of ColumbiaAges 5–21 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT07180537Recruiting
Health course for joint and mood conditions
This study tests an online health course that helps improve diet and self-care to support cell health and wellbeing. It is for people with certain rheumatological conditions like rheumatoid arthritis, lupus, or psoriatic arthritis, who also have mood concerns.
Iowa City, IowaAges 18–100 - NCT03152058RecruitingPhase 2
Certolizumab for pregnancy in people with APS
This Phase 2 study tests whether certolizumab can improve pregnancy outcomes in people with antiphospholipid syndrome (APS). It targets pregnancy complications related to APS while closely checking safety, infections, and certain health conditions.
New York, New YorkAges 18–40
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 343 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.